<DOC>
	<DOCNO>NCT00000755</DOCNO>
	<brief_summary>To examine response HIV-1 infect patient vaccination gp120/HIV-1MN antigen . To determine effect antiretroviral therapy vaccine responsiveness . Fifty percent HIV-1 infected individual remain symptom free 8-12 year . It hypothesize HIV-specific immune response responsible period relative quiescence viral replication . Recent study suggest immune function augment vaccination HIV-derived antigen .</brief_summary>
	<brief_title>A Phase I/II Trial Vaccine Therapy HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3</brief_title>
	<detailed_description>Fifty percent HIV-1 infected individual remain symptom free 8-12 year . It hypothesize HIV-specific immune response responsible period relative quiescence viral replication . Recent study suggest immune function augment vaccination HIV-derived antigen . Patients randomized receive rgp120/HIV-1MN vaccine alum adjuvant placebo intramuscular injection week 0 , 4 , 8 , 12 , 16 , 20 , without daily oral zidovudine ( AZT ) current stable dose antiretroviral therapy . After complete primary vaccination series , patient permit continue extension phase , receive booster vaccination week 28 , 36 , 44 . Patients stratify CD4 count : 350-500 , 200-349 , 50-199 cells/mm3 . A fourth group count 350-500 cells/mm3 serve pilot group receive vaccine .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Required immediately prior study entry : A minimum 2 maximum 12 month AZT therapy 500600 mg/day ( apply pilot group patient receive vaccine patient CD4 count 50199 cells/mm3 ) . Concurrent Medication : Allowed : PCP prophylaxis . Rifabutin clarithromycin ( patient CD4 count 50199 cells/mm3 ) . Shortterm nonsteroidal antiinflammatory therapy acute condition . Short intermittent cycle acyclovir . Patients must : HIV infection , CD4 count 50500 cells/mm3 . No active opportunistic infection ( patient CD4 count 50199 cells/mm3 may history opportunistic infection ) . Consent parent , guardian , person power attorney , less 18 year age . Bcell line establish order vaccinate . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Known suspected allergy vaccine component . Concurrent Medication : Excluded : Agents immunosuppressive activity . Antiretroviral therapy AZT ( except patient CD4 count 50199 cells/mm3 ) . Interferon . Parenteral therapy ( include SC allergy medication chemotherapy Kaposi 's sarcoma ) . Steroids . Hematopoietins . Prior Medication : Excluded within 12 week prior study entry : Agents immunosuppressive activity . Antiretroviral therapy AZT ( except patient CD4 count 50349 cells/mm3 ) . Interferon . Parenteral therapy ( include SC allergy medication chemotherapy Kaposi 's sarcoma ) . Steroids . Hematopoietins . Active drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Therapeutic Vaccine</keyword>
</DOC>